Literature DB >> 10353641

A catalytic mechanism for caspase-1 and for bimodal inhibition of caspase-1 by activated aspartic ketones.

K D Brady1, D A Giegel, C Grinnell, E Lunney, R V Talanian, W Wong, N Walker.   

Abstract

We have evaluated 619 aspartic ketones with 9 different types of prime-side groups (acyloxymethyl, aryloxymethyl, arylthiomethyl, alkylthiomethyl, acylamino-oxymethyl, sulfonylaminomethyl, alpha-ketoamide, alpha-(1-phenyl-3-trifluoromethyl-pyrazol-5-yl)oxymethyl (PTP), and aliphatic ketones) as inhibitors of caspase-1. The inhibitory behaviors could be classified as reversible, inactivating, or bimodal (i.e. reversible inhibition followed by slow inactivation) based on the kinetically observed formation of reversible thiohemiketal complexes and conversion to an irreversible thioether adduct, and the mechanism of any given ketone was only poorly predictable on the basis of leaving group structure and chemistry. Among 201 bimodal inhibitors, the rate of conversion of the reversible thiohemiketal complex to the inactive thioether (k(i)) was strictly first-order, consistent with direct conversion of the thiohemiketal to the thioether with no intermediate collapse to free ketone and thiolate. We have examined 22 crystallographic structures of caspase-1 complexed as a thiohemiketal with the inhibitors from 8 different ketone classes, and found the Cys285S-C-C(alpha)-leaving group dihedral angle to be near either to 60 degrees or to 180 degrees. Only the 180 degrees conformation was permissive for SN2 displacement of the leaving group and, furthermore, positioned His237Ndelta to stabilize developing charge on the leaving group. Among these structures and 19 additional complexes, all showed a strong interaction between His237Ndelta and the ketone or thiohemiketal oxygen. We therefore propose a proteolytic mechanism for caspase-1 involving polarization of the scissile carbonyl by the His237 imidazolium group. During thiohemiketal/thioether conversion (but probably not during peptide hydrolysis), the leaving group is stabilized by the His237 imidazolium.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10353641     DOI: 10.1016/s0968-0896(99)00009-7

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  17 in total

Review 1.  The protein structures that shape caspase activity, specificity, activation and inhibition.

Authors:  Pablo Fuentes-Prior; Guy S Salvesen
Journal:  Biochem J       Date:  2004-12-01       Impact factor: 3.857

2.  Mechanistic and structural studies on legumain explain its zymogenicity, distinct activation pathways, and regulation.

Authors:  Elfriede Dall; Hans Brandstetter
Journal:  Proc Natl Acad Sci U S A       Date:  2013-06-17       Impact factor: 11.205

3.  Development of an advanced nanoformulation for the intracellular delivery of a caspase-3 selective activity-based probe.

Authors:  Francesco Cogo; Marcin Poreba; Wioletta Rut; Katarzyna Groborz; Peter Smyth; Michael C Johnston; Richard Williams; Daniel B Longley; Roberta E Burden; Guy S Salvesen; Marcin Drag; Christopher J Scott
Journal:  Nanoscale       Date:  2019-01-03       Impact factor: 7.790

Review 4.  Small Molecule Active Site Directed Tools for Studying Human Caspases.

Authors:  Marcin Poreba; Aleksandra Szalek; Paulina Kasperkiewicz; Wioletta Rut; Guy S Salvesen; Marcin Drag
Journal:  Chem Rev       Date:  2015-11-09       Impact factor: 60.622

5.  Caspase selective reagents for diagnosing apoptotic mechanisms.

Authors:  Marcin Poreba; Katarzyna Groborz; Mario Navarro; Scott J Snipas; Marcin Drag; Guy S Salvesen
Journal:  Cell Death Differ       Date:  2018-05-10       Impact factor: 15.828

Review 6.  The potential for caspases in drug discovery.

Authors:  Sarah H MacKenzie; Joshua L Schipper; A Clay Clark
Journal:  Curr Opin Drug Discov Devel       Date:  2010-09

7.  Structure-based combinatorial library design: discovery of non-peptidic inhibitors of caspases 3 and 8.

Authors:  M S Head; M D Ryan; D Lee; Y Feng; C A Janson; N O Concha; P M Keller; W E deWolf
Journal:  J Comput Aided Mol Des       Date:  2001-12       Impact factor: 3.686

8.  Nonpeptidic tetrafluorophenoxymethyl ketone cruzain inhibitors as promising new leads for Chagas disease chemotherapy.

Authors:  Katrien Brak; Iain D Kerr; Kimberly T Barrett; Nobuhiro Fuchi; Moumita Debnath; Kenny Ang; Juan C Engel; James H McKerrow; Patricia S Doyle; Linda S Brinen; Jonathan A Ellman
Journal:  J Med Chem       Date:  2010-02-25       Impact factor: 7.446

9.  Identification of a new class of nonpeptidic inhibitors of cruzain.

Authors:  Katrien Brak; Patricia S Doyle; James H McKerrow; Jonathan A Ellman
Journal:  J Am Chem Soc       Date:  2008-04-25       Impact factor: 15.419

Review 10.  Thioredoxins, glutaredoxins, and peroxiredoxins--molecular mechanisms and health significance: from cofactors to antioxidants to redox signaling.

Authors:  Eva-Maria Hanschmann; José Rodrigo Godoy; Carsten Berndt; Christoph Hudemann; Christopher Horst Lillig
Journal:  Antioxid Redox Signal       Date:  2013-03-28       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.